drugset / Trial / NCT02216877

Magnesium Supplementation for Hypomagnesemia in Chronic Kidney Disease

NCT02216877 ↗

Phase 1/2 Completed 36 enrolled Zealand University Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

Randomized placebo-controlled interventional trial to investigate the effect of oral magnesium supplementation on intracellular magnesium in subjects with chronic kidney disease. We hypothesize that oral magnesium supplementation will increase intracellular magnesium in subjects with chronic kidney disease as well as increase serum magnesium.

Timeline

Start
2014-08
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Mablet Unknown 360 mg Oral